This pattern gives a first target to return to level A at about 8.10-8.20 and a second target to return to level C at around 8.50.
Anticipated Catalysts for remaining 2022:
NA/US Licensing Vyleesi
ROW Licensing Vyleesi
PL3994 PH2 Heart Failure Data
Diabetic Nephropathy PH 2 Initiate Study
Something should also happen with the preferred shares at the end of September. (Convertible at $11.25 to common shares, Redeemed for debt, or basically cancelled)
Anticipated Catalysts for remaining 2022:
NA/US Licensing Vyleesi
ROW Licensing Vyleesi
PL3994 PH2 Heart Failure Data
Diabetic Nephropathy PH 2 Initiate Study
Something should also happen with the preferred shares at the end of September. (Convertible at $11.25 to common shares, Redeemed for debt, or basically cancelled)